Elan Corporation Plc said that it has hired Citigroup Global Markets Inc to help it review its strategic options, including a possible alliance, merger or a sale. The review follows a decline in the company’s share price since July 2008 amid concerns about adverse events related to its multiple sclerosis drug, Tysabri (natalizumab).
